EF Hutton initiated coverage of Anixa Biosciences with a Buy rating and $10 price target. Anixa is a biotechnology company that harnesses the immune system to fight cancer, the analyst tells investors in a research note. The firm says the company’s lead program involves developing a CAR-T therapy targeting solid tumors. The company is also developing cancer vaccines, including one for triple-negative breast cancer and another for ovarian cancer, EF points out.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Anixa Biosciences’ IND for ovarian cancer CAR-T therapy approved by FDA
- Anixa Biosciences announces Japanese patent on breast cancer vaccine technology
- Anixa Biosciences announces $5M share repurchase program
- Anixa Biosciences treats sixth patient in ovarian cancer CAR-T clinical trial
- Anixa Biosciences price target lowered to $7 from $12 at H.C. Wainwright